Wockhardt Limited has announced that the Indian drug regulator has granted marketing authorization for its antibiotic ZAYNICH® for treating complicated urinary tract infections. The press release highlights ZAYNICH®'s potential as a life-saving option against resistant infections, particularly in cases where current treatments are limited.
Pursuant to Regulation 30 of Listing Regulations, please find enclosed Press Release titled, Indian drug regulator grants marketing authorization to Wockhardt's breakthrough antibiotic, ZAYNICH® (Zidebactam/ Cefepime), for treatment of complicated urinary tract infections including pyelonephritis with concurrent Gram-negative bacteremia.